TrialTransplantation and cellular therapy2023

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.

Qaiser Bashir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.